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Novel Quantitative Immunofluorescent Technique Reveals
Improvements in Epidermal Cell Populations after Mild Treatment
of Psoriasis
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A novel antibody labelling technique, the Zenon technique,
was used in fluorescent immunohistochemistry for a better
characterization of epidermal cell populations in a
quantitative approach. With this technique, differences
in proliferation and differentiation characteristics were
shown between psoriatic and normal epidermis. The
sensitivity of the method was investigated by assessing
the effect of a mild topical treatment versus an emollient.
Frozen sections of non-treated psoriatic epidermis and
psoriatic epidermis treated once daily with either an
emollient or betamethasone-17-valerate for only 2 weeks
were compared immunohistochemically. Antibodies
against keratin 6, 10 and 15 were labelled with the
Zenon technique, whereas antibodies against the Ki-67
antigen and b-1 integrin were covalently FITC-labelled.
Using image analysis, these markers were measured in the
epidermis in a standardized manner.
Treatment of psoriasis with short-term topical steroid
resulted towards normalization of Ki-67 antigen, b-1
integrin, keratin 10 and keratin 6 expression, which are
parameters for proliferation and differentiation. Although
treatment with an emollient showed hardly any clinical
response, changes towards a more normal phenotype could
already be detected in several epidermal markers using
this method. Key words: Zenon; immunohistochemistry;
psoriasis; epidermis.
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The epidermis is a constantly renewing epithelium. The
capacity for self-renewal of the epidermis is presumed to
be preserved by stem cells, which are situated in the
basal layer. These stem cells develop transient amplify-
ing cells (TACS), which have a limited capacity to
proliferate before differentiation and formation of a
corneocyte (1–3). Psoriasis is characterized by epidermal
hyperproliferation, disturbed differentiation and inflam-
mation. It has been shown that the process of
keratinocyte differentiation is altered in psoriasis.
According to our current understanding psoriasis
should be considered a T-cell-mediated disease.
Therefore, T cells are supposed to have a regulatory
role in the altered keratinocyte differentiation. Indeed,
specific anti-T-cell treatments, such as alefacept and
efalizumab, have a substantial therapeutic efficacy in
psoriasis (4). Established anti-psoriatic treatments have
more broad effects on various aspects in the pathogen-
esis of psoriasis. Topical vitamin D analogues and
corticosteroids inhibit the proliferation of epidermal
keratinocytes and the former drug also enhances the
cornified envelope formation, which indicates an effect
on keratinocyte differentiation (5). Furthermore, appli-
cation of an emollient also seems effective to some
extent, resulting in a slight modification of proliferation
and differentiation (6–8).
Increased recruitment of cycling epidermal cells has
been shown to be the most important mechanism of
epidermal proliferation in psoriasis. This pheno-
menon can be quantified by calculating the number of
Ki-67-positive nuclei, which is impressively increased in
the psoriatic epidermis (9–13). The altered differentia-
tion in the psoriatic epidermis is shown by the
replacement of keratin 10, representing differentiating
cells, by keratin 6 (14–19). b-1 Integrin expression in the
basal layer is important for studying stem cells, which
reside in this compartment (2, 20–23). Keratin 15 may
be a marker for stem cells in the hair follicle and is also
expressed in the basal layer of the interfollicular
epidermis. However, expression of keratin 15 disappears
in a hyperproliferative state like psoriasis (24, 25).
Major differences in expression of the above-mentioned
epidermal cell markers between normal and psoriatic
epidermis were shown with fluorescent immunohistochem-
istry using the Zenon technique, a novel labelling
technique (26). This technique is a simple and rapid
technique. It conjugates primary antibodies quantitatively
and the labelled antibodies can be used in the same way
as covalently labelled primary antibodies (27). The
combination of this technique with image analysis
offers a possibility to describe morphology and show co-
expression of proteins. Co-expression is demonstrated
by labelling two antibodies with different fluoro-
chromes. Using a combination of a proliferation and a
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differentiation marker is useful for the demonstration of
TACs, which migrate from the basal layer into the upper
layers of the epidermis. After being released from the basal
layer, expression of b-1 integrin on their cell surface is still
present but diminished. After proliferation, these cells
become committed to terminal differentiation and express
both Ki-67 and keratin 10. The effect of treatment on the
differentiation process is reflected by co-expression of
keratin 10 and keratin 6, which can be quantified with this
technique (26).
The aim of the present study was to investigate the
sensitivity of the combination of the Zenon technique
with standardized image analysis, i.e. to see whether or
not minor differences in expression patterns of epider-
mal markers for proliferation and differentiation could




After obtaining informed consent, skin punch biopsy speci-
mens were collected from five patients (four women and one
man, aged 57.6 years¡8.8) with mild-to-moderate plaque
psoriasis. They did not receive any topical treatment for at
least 2 weeks or systemic therapy for at least 4 weeks before
specimens were obtained. A 4-mm punch biopsy was taken
from two representative lesions after local anaesthesia with
xylocaine 1%/adrenaline. One lesion was then treated with
betamethasone-17-valerate 0.1% cream once daily, while the
other lesion was treated with an emollient (50% cremor lanette
I (15 g lanette wax SX, 20 g cetiol V, 4 g sorbitol solution,
0.15 g sorbinic acid, aqua ad 100 g) in vaselinum album;
vaseline-lanette). After 2 weeks of treatment, a second 4-mm
punch biopsy was taken. All specimens were embedded in
Tissue-Tek (Sakura Finetek, Zoeterwoude, The Netherlands),
snap-frozen in liquid nitrogen and stored at 280 C˚. Frozen
sections were chosen because of their advantages regarding the
use of surface antigens and fluorescent techniques.
Erythema, infiltration and scaling of the lesions were
recorded using a 5-point scale from 05‘none’ to 45‘extremely
severe’ before and after treatment. The SUM score, which is
the total score for erythema, infiltration and scaling, was
calculated.
Fluorescent immunohistochemistry and Zenon labelling
technique
This method has been described previously (26). In brief, the
Zenon labelling technique makes it possible to label a primary
antibody rapidly and quantitatively, which can be used in the
same way as covalently labelled primary antibodies. With this
technique, the primary antibodies are specifically coupled with
fluorescent-labelled Fab fragments of secondary antibodies
directed against their Fc regions. The Zenon technique was used
according to the protocol of the manufacturer (Molecular
Probes, Eugene, USA) with minor modifications. Monoclonal
antibodies were labelled and/or diluted and incubated on 6-mm
frozen sections of the biopsies. Monoclonal antibodies against
keratin 10 (Monosan, Uden, The Netherlands; RKSE60) and
keratin 6 (Novocastra Laboratories, Newcastle upon Tyne, UK;
LHK6B) were labelled using the Zenon labelling technique
and were used for examination of epidermal differentiation.
For assessment of epidermal proliferation, Ki-67 antigen
(DakoCytomation, Copenhagen, Denmark; MIB-1 FITC),
covalently FITC-labelled, was used. Monoclonal antibodies
against b-1 integrin (DakoCytomation, Copenhagen, Denmark;
CD29 FITC, clone K20) and keratin 15 (Neomarkers, Fremont,
USA; LHK15) were used for analysis of the basal layer of the
epidermis. b-1 Integrin was covalently labelled with FITC,
whereas keratin 15 was labelled using the Zenon labelling
technique.
For the double-staining procedure, equal volumes of two
antibody dilutions were mixed and incubated on the slides.
Keratin 10 was combined with Ki-67, with b-1 integrin and
with keratin 6, while b-1 integrin was also mixed with keratin
15. The initial manufacturers’ concentrations of the antibodies
were diluted in 1% bovine serum albumin (BSA: Sigma, St
Louis, USA) in phosphate-buffered saline and used in the
following concentrations: anti-keratin 10 and anti-keratin 6,
1:30; anti-b-1 integrin, 1:100; and anti-Ki-67 antigen and anti-
keratin 15, 1:50.
The sections and monoclonal antibodies were examined
using an immunofluorescence microscope (Axioskop 2 MOT,
Zeiss) and images were photographed using a digital
camera (Sony, DXC-390P 3 CCD) and ‘Image J’ software
(Scanalytics, Fairfax, USA). Photography was standardized by
setting the shutter off and by securing the light intensity. Total
exposure to light was less than 5 seconds for each frame. For
each antibody, 10 different parts of the epidermis were
photographed. These images were analysed with IP-lab soft-
ware (Scanalytics) in a standard manner. The intensity and
percentage of positive signal in the epidermis was measured
with standardized settings.
For double-staining and co-expression, photographs of the
same part of the epidermis were taken for each antibody by
switching to the correct filters and light intensity and these
pictures were merged using IP-lab.
Statistical analysis
Statistical analysis was performed using a t-test: two-sample
assuming unequal variances and standard regression software
and a t-test: paired two samples for means. p values of v0.05
were considered statistically significant. Mean¡SEM are used.
RESULTS
The clinical SUM scores revealed a reduction in
erythema, induration and scaling for both vaseline-
lanette and betamethasone-17-valerate treatment (from
5.6¡0.7 to 4.6¡0.5 and from 6.0¡0.7 to 2.8¡0.2
(mean¡SEM), respectively). However, only the latter
response was statistically significant (pv0.05).
Ki-67 expression revealed a significant reduction from
112¡8.1 positive cell nuclei per mm basal membrane
before treatment to 48¡4.1 positive cell nuclei per mm
basal membrane after treatment with betamethasone-17-
valerate (pv0.05). Treatment with vaseline-lanette also
showed a significant decrease from 98¡7.6 to 65¡5.8
positive cell nuclei per mm basal membrane after treatment
(pv0.05). The reduction after betamethasone-17-valerate
treatment was significantly higher (pv0.05) as compared
with the improvement following vaseline-lanette treat-
ment of these plaques (Fig. 1A). However, no statistically
significant differences were found in the vaseline-lanette-
and betamethasone-17-valerate-treated psoriatic lesions
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when comparing the results paired per patient (p50.10 and
p50.17, respectively). A tendency towards normalization
is shown (Fig. 1B).
b-1 Integrin is expressed in the basal and some
suprabasal layers in the untreated psoriatic epidermis.
After treatment, the expression in the suprabasal
layers was diminished and more confined to the basal
layer (Fig. 3). The increase of positive surface area for
b-1 integrin reached statistical significance for both
vaseline-lanette and betamethasone-17-valerate (from
9.9¡0.4% to 11.4¡0.6% and from 9.9¡0.5% to
13.2¡0.7%, respectively (pv0.05) with a statistically
higher increase for betamethasone-17-valerate com-
pared with vaseline-lanette (pv0.05) (Fig. 1C). Also,
for b-1 integrin intensity a significantly higher increase
was found for both vaseline-lanette and betamethasone-
17-valerate treatment (from 81.6¡2.3 FU to 96.3¡
2.9 FU and from 89.3¡3.1 FU to 107.2¡2.9 FU,
Fig. 1. (A) Number of Ki-67-positive nuclei /mm length of basement membrane before (grey bar) and after (black bar) treatment (*pv0.05). (B)
Number of Ki-67-positive nuclei before and after treatment with vaseline-lanette and betamethasone-17-valerate per patient (the symbols in the
vaseline-lanette- and betamethasone-treated group refer to the same patient). (C) b-1 Integrin-positive surface area as a percentage of epidermis
before (grey bar) and after (black bar) treatment. (D) Intensity of b-1 integrin expression assessed as units of fluorescence before (grey bar) and
after (black bar) treatment. (E) Keratin 10-positive surface area as a percentage of epidermis before (grey bar) and after (black bar) treatment. (F)
Intensity of keratin 10 expression assessed as units of fluorescence before (grey bar) and after (black bar) treatment. (G) Keratin
6-positive surface area as a percentage of epidermis before (grey bar) and after (black bar) treatment. (H) Intensity of keratin 6 expression
assessed as units of fluorescence before (grey bar) and after (black bar) treatment.
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respectively; pv0.05) (Fig. 1D). Due to statistically
unequal intensities for b-1 integrin between both sets of
untreated plaques, the difference in increase for vase-
line-lanette and betamethasone-17-valerate could not
be compared.
Keratin 10 has a suprabasal expression pattern, which
is heterogeneous in the untreated psoriatic lesion and
becomes more homogenous after treatment (Figs 2 and
3). Keratin 10 expression showed a significant increase
in positive surface area following both vaseline-
lanette and betamethasone-17-valerate treatment (from
29.7¡2.3% to 44.6¡2.5% and from 40.2¡2.9% to
46.9¡1.8%, respectively; pv0.05). These increases
cannot be compared with each other because of
significantly different positive surface areas for keratin
10 between both untreated plaques. For the intensity of
keratin 10 a significant increase was seen after beta-
methasone-17-valerate treatment (from 132.9¡3.2 FU
to 145.3¡1.9 FU; pv0.05), while the increase with
vaseline-lanette treatment from 128.2¡3.3 FU to
135.2¡3.1 FU did not reach statistical significance
(p50.12). While keratin 10 intensity was equal in both
sets of untreated plaques, betamethasone-17-valerate
treatment revealed a significantly higher increase of
Fig. 2. Double-staining of Ki-67 (green) with keratin 10 (red) before treatment (A), after treatment with vaseline-lanette (B) and after treatment
with betamethasone-17-valerate (C).
Fig. 3. Double-staining of b-1 integrin (green) with keratin 10 (red) before treatment (A), after treatment with vaseline-lanette (B) and after
treatment with betamethasone-17-valerate (C).
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intensity in comparison with vaseline-lanette treatment
(Fig. 1E, F).
Keratin 6 is also expressed in the suprabasal layers of
the epidermis in psoriatic lesions. In the untreated
lesions a more homogenous pattern of expression was
seen, while after 2 weeks of treatment the pattern was
more heterogeneous (data not shown). A significant
decrease within the same range was found for
positive surface area after both vaseline-lanette and
betamethasone-17-valerate treatment (from 56.9¡1.5%
to 45.5¡2.3% and from 58.2¡1.6% to 40.9¡3.2%,
respectively; pv0.05) with no statistical differences
between both untreated plaques (p50.58) (Fig. 1G).
For keratin 6 intensity, vaseline-lanette treatment
showed a significant decrease (from 187.2¡2.7 FU to
173.9¡3.8 FU; pv0.05). Betamethasone-17-valerate
also revealed a decrease in intensity (from 187.8¡
2.8 FU to 180.1¡4.3 FU), which did not reach
statistical significance (p50.14) (Fig. 1H).
Untreated psoriatic lesions did not express keratin 15;
neither treatment with betamethasone-17-valerate nor
with vaseline-lanette resulted in its expression.
Double staining of Ki-67 with keratin 10 visualizes an
overlap in expression in both vaseline-lanette- and
betamethasone-17-valerate-treated epidermis. Some
Ki-67-positive nuclei reside in keratin 10-positive cells.
However, Ki-67-positive nuclei are more confined to the
basal layer after betamethasone-17-valerate treatment,
whereas in untreated and with vaseline-lanette-treated
psoriatic epidermis, Ki-67-positive nuclei are also
present in suprabasal layers (Fig. 2).
In the double-staining of b-1 integrin with keratin 10,
b-1 integrin-positive cells are found in the basal layer
after treatment with betamethasone-17-valerate. Also, in
this treatment group, a few cells, which express both
beta-1 integrin and keratin 10, are seen. In the untreated
epidermis and the epidermis treated with vaseline-
lanette, no co-expression was shown (Fig. 3).
Double-staining of keratin 6 with keratin 10 in the
untreated epidermis shows keratinocytes expressing
both keratin 6 and keratin 10 (yellow/orange cells) and
keratinocytes only expressing keratin 6 (green cells).
These double-positive cells are localized throughout the
epidermis. No cells that were only positive for keratin
10 were seen in the untreated epidermis. However,
following treatment with betamethasone-17-valerate,
the epidermis revealed cells that only expressed keratin
10 (Fig. 4).
DISCUSSION
In order to demonstrate the sensitivity of the combina-
tion of the Zenon labelling technique and microscopic
image analysis, the effect of a mild treatment and an
emollient on the psoriatic epidermis was investigated.
Betamethasone-17-valerate in a cream base was used
once daily for 2 weeks and this can be regarded as a mild
treatment (5). The effect of such a mild corticosteroid
treatment is markedly different from a potent or ultra-
potent corticosteroid. For example, a potent cortico-
steroid diminishes proliferation, resulting in a reduction
of the number of Ki-67-positive nuclei below the normal
range after treatment (28).
Although emollients have a slight clinical effect on the
psoriatic skin, it has been shown in previous studies that a
Fig. 4. Double-staining of keratin 6 with keratin 10 before treatment (A), after treatment with vaseline-lanette (B) and after treatment with
betamethasone-17-valerate (C).
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vehicle alone also has a small therapeutic effect in the
psoriatic epidermis (29, 30). Therefore, treatment with an
emollient was chosen to investigate the sensitivity of this
novel method to quantify proliferation and differentiation
aspects in the epidermis. A decrease of proliferation, which
is shown by a diminished number of Ki-67-positive nuclei
and an increase of b-1 integrin surface area and intensity
was seen following treatment with the corticosteroid. The
b-1 integrin-positive surface area increases during treat-
ment, while the epidermis clearly loses its suprabasal b-1
integrin expression. The b-1 integrin-positive surface area
is measured relative to the thickness of the epidermis (total
surface area). Because of decreasing number of cell layers
in the epidermis during treatment and therefore the total
surface area, the b-1 integrin-positive surface area can
increase relatively. The improvement of the differentiation
markers, keratin 6 and keratin 10, was evident but less
prominent. For keratin 10, this had been observed in
earlier studies (31). Although treatment with vaseline-
lanette only tends to provide a slight improvement
clinically, differences were already evident for all epidermal
markers using this novel method. The present methodol-
ogy permits demonstration of the anti-psoriatic effect of a
mild treatment and even an emollient on the epidermis,
which only causes a subtle clinical improvement.
An anti-proliferative effect of emollients has been shown
in the literature, which is confirmed by these data (7, 29).
The double-staining, however, still reveals the presence of
Ki-67-positive nuclei in the keratin 10-positive compart-
ment and co-expression of b-1 integrin and keratin 10 is
not present, suggesting that emollients do not influence the
suprabasal compartment, which contains late TACs.
Although double-staining of keratin 6 and keratin 10
shows more co-expression of both proteins after treatment
with an emollient, cells expressing only keratin 10 are not
present. However, a small effect of an emollient on
keratinocyte differentiation is shown.
The effect of a mild corticosteroid on the suprabasal
compartment is more evident. After treatment with a
corticosteroid, the Ki-67-positive nuclei are more con-
fined to the basal layer, the suprabasal expression of b-1
integrin disappears and keratin 10 expression occurs just
above the basal layer. An effect on differentiation is
indicated in the double-staining of keratin 6 and keratin
10, which reveals a few cells expressing only keratin 10.
Therefore, double-staining clearly differentiated the
effect of a topical corticosteroid from an emollient,
focusing on the TACs as target cells for pharmacologi-
cal intervention.
Probably owing to the relatively small number of
participating patients in this study, the differences
mentioned above were not found to be statistically
significant by analysing the data paired per patient.
However, this study was not designed to investigate the
size of the therapeutic effect, but to show the sensitivity
of this method. Therefore only mild therapies were used.
In our opinion, comparison of the data using a t-test in a
non-paired manner was permitted.
In conclusion, the methodology presented in this
communication permits highly sensitive discrimination
of anti-psoriatic effect of an active treatment versus
an emollient. Corticosteroids affect the suprabasal
compartment, probably by affecting the TACs. Further
studies on the role of TACs in mediating therapeutic
effects of anti-psoriatic treatments are worthwhile.
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